Rigel Pharmaceuticals Inc

More

• 5 Stocks Poised for Breakouts: Technical Analysis Monday, 15 Apr 2013 | 4:00 PM ET

  

  The pros know that once a stock starts to break past resistance levels, it can easily trend significantly higher. TheStreet.com looks at five stocks.

• UPDATE 3-AstraZeneca, Rigel arthritis pill disappoints again Friday, 5 Apr 2013 | 9:48 AM ET

  *Rigel shares slump 33 pct, AstraZeneca little changed. LONDON, April 5- AstraZeneca's experimental rheumatoid arthritis pill fostamatinib met only one of two goals in a late-stage clinical trial, leaving the future of one of the group's few advanced pipeline products uncertain.

• UPDATE 2-AstraZeneca arthritis pill performs poorly in new study Friday, 5 Apr 2013 | 5:51 AM ET

  LONDON, April 5- AstraZeneca's experimental rheumatoid arthritis pill fostamatinib met only one of two goals in a late-stage clinical trial, leaving the future of one of the group's few advanced pipeline products uncertain.

• UPDATE 3-Hopes fade for AstraZeneca and Rigel's arthritis pill Thursday, 13 Dec 2012 | 10:37 AM ET

  *Analysts' expectations for AstraZeneca, Rigel product low. *AstraZeneca shares fall 3 percent, Rigel dives 31 percent. LONDON, Dec 13- An experimental rheumatoid arthritis drug from AstraZeneca proved inferior to Abbott Laboratories' Humira in a clinical study, knocking hopes for one of the few late-stage products in the company's pipeline.

• UPDATE 2-AstraZeneca arthritis drug lags Abbott's Humira in test Thursday, 13 Dec 2012 | 4:27 AM ET

  *Analyst expectations for AstraZeneca product already low. LONDON, Dec 13- An experimental rheumatoid arthritis drug from AstraZeneca proved inferior to Abbott Laboratories' Humira in a clinical study, knocking hopes for one of the few late-stage products in the company's pipeline.